Lupus nephritis: Through the looking-glass

Lupus

Volumn 24, Issue 6, 2015, Pages 533-535

  Whittier, William Luke ^a   Reiser, J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ANTIGEN ANTIBODY COMPLEX; CHRONIC KIDNEY DISEASE; EDITORIAL; EPITHELIUM CELL; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LUPUS ERYTHEMATOSUS NEPHRITIS; NECROTIZING ARTERITIS; NEPHROTIC SYNDROME; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; GENETICS; IMMUNOLOGY; LUPUS NEPHRITIS; PATHOLOGY; PHYSIOLOGY;

BIOMARKERS; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; LUPUS NEPHRITIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84928040368     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314560006     Document Type: Editorial

References (28)

1. Carroll L Through the Looking-Glass, and What Alice Found There. London: Macmillan and Company ; 1871 :
2. Lewis EJ, Schwartz MM. Pathology of lupus nephritis. Lupus. 2005 ; 14: 31-38
3. Churg J, Bernstein J, Glassock R (eds). Lupus nephritis. In: Renal disease: classification and atlas of glomerular diseases. New York: Igaku-Shoin, 1995. pp. 151-180.
4. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 ; 15: 241-250
5. Behara VY, Whittier WL, Korbet SM, Schwartz MM, Martens M, Lewis EJ. Pathogenetic features of severe segmental lupus nephritis. Nephrol Dial Transplant. 2010 ; 25: 153-159
6. Hill GS, Delahousse M, Nochy D, Bariety J. Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005 ; 68: 2288-2297
7. Schwartz MM, Roberts JL, Lewis EJ. Necrotizing glomerulitis of systemic lupus erythematosus. Hum Pathol. 1983 ; 14: 158-167
8. Schwartz MM. Lupus vasculitis. Contrib Nephrol. 1992 ; 99: 35-45
9. Schwartz MM, Korbet SM, Katz RS, Lewis EJ. Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus. 2009 ; 18: 149-158
10. Dooley M. Clinical manifestations of lupus nephritis. In: Lewis E, Schwartz MM, Korbet SM, Chan T (eds), Lupus nephritis. New York, USA: Oxford University Press, 2011. pp. 1-34.
11. Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus. 2006 ; 15: 71-75
12. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005 ; 16: 175-179
13. Lewis EJ. Lupus podocytopathy. In: Lewis EJ, Schwartz MM, Korbet SM, Chan T (eds), Lupus nephritis. New York, USA: Oxford University Press, 2011. pp. 199-210.
14. Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: A large cohort study from a single centre. Rheumatology (Oxford). 2014 ; 53: 1235-1244
15. Desai N, Cimbaluk D, Lewis EJ, Whittier WL. Proteinuria in membranous lupus nephritis: The pathology is in the podocyte. Lupus. 2013 ; 22: 461-468
16. Toldi G, Szalay B, Beko G, et al. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers. 2012 ; 17: 758-763
17. Wei C, Moller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008 ; 14: 55-63
18. Wei C, El HS, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011 ; 17: 952-960
19. Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013 ; 96: 649-656
20. Zhang B, Shi W, Ma J, et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl). 2012 ; 90: 1407-1420
21. Maile LA, Busby WH, Gollahon KA, et al. Blocking ligand occupancy of the alphaVbeta3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology 2014; 155: 4665-4675.
22. Moysiadis DK, Perysinaki GS, Bertsias G, et al. Early treatment with glucocorticoids or cyclophosphamide retains the slit diaphragm proteins nephrin and podocin in experimental lupus nephritis. Lupus. 2012 ; 21: 1196-1207
23. Perysinaki GS, Moysiadis DK, Bertsias G, et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus. 2011 ; 20: 781-791
24. Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014 ; 6: 256ra136
25. Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015; 26: 133-147.
26. Li Y, Fang X, Li QZ. Biomarker profiling for lupus nephritis. Genomics Proteomics Bioinformatics. 2013 ; 11: 158-165
27. Rovin BH, Zhang X. Biomarkers for lupus nephritis: The quest continues. Clin J Am Soc Nephrol. 2009 ; 4: 1858-1865
28. Rovin BH, Parikh SV. Lupus nephritis: The evolving role of novel therapeutics. Am J Kidney Dis. 2014 ; 63: 677-690